Umoja Biopharma raises $53M Series A to develop in vivo CAR T-cell immunotherapies for adult and pediatric tumors

Seattle-based Umoja Biopharma raised $53 million in a Series A to advance its preclinical in vivo CAR T-cell immunotherapy platform for blood and organ tumors in adult and pediatric patients, aiming to generate cancer-fighting cells inside the body. The company was founded last year by CEO Andy Scharenberg and collaborators from Seattle Children’s Research Institute and Purdue University, with MPM Capital and Qiming Venture Partners USA leading the round.

AAndy Scharenberg UUmoja Biopharma UUniversity of Washington